Predicting response to GLP-1-based therapy in MASLD/MASH: an evidence-tiered, endpoint-specific framework built on host genotype and gut microbial features
This review examines the variability in benefit from incretin-based therapy for metabolic dysfunction-associated steatohepatitis (MASH). It proposes that liver benefits from GLP-1 receptor agonists are indirect, mediated by weight loss and gut-liver signaling. The authors assemble evidence on host genotype and gut microbial features into a framework to predict patient response, grading findings by evidence maturity and separating liver and cardiovascular benefits.
What to check after reading
The framework separates liver and cardiovascular benefit predictions and notes that a predicted poor liver response is not a reason to stop GLP-1 therapy.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.